YPD-01 / YepBio - LARVOL DELTA

Multi-omics insights into co-fermentation by Saccharomycopsis fibuligera and Bacillus velezensis enhancing the nutritional, metabolic, and aromatic quality of Pueraria thomsonii. (PubMed, Front Nutr) - "Solid-state fermentation (SSF) was conducted at 30 °C for 72 h under microaerophilic conditions across five treatments: raw P. thomsonii (Y), natural fermentation (K), single-strain fermentation with S. fibuligera YPD01 (S) or B. velezensis NA03 (B), and co-fermentation with both strains at a 1:1 ratio (M)...Co-fermentation outperformed both natural and single-strain fermentations in the release of phenolic compounds and isoflavone aglycones, amino acid enrichment, and flavor development. These findings provide a theoretical basis and technical guidance for developing high-value fermented foods and offer a reference framework for the precision microbial transformation of medicinal and edible homologous materials."

Journal

HLB bioStep announced on July 16 that YepBio’s Parkinson’s disease treatment candidate, ’YPD-01’ (development code), for which HLB bioStep, along with its subsidiary HLB bioCode, supported preclinical development, has received approval from Korea’s Ministry of Food and Drug Safety (MFDS) for its Phase 1 clinical trial application (IND). [Google translation] (The Bio)

New P1 trial • Parkinson's Disease